This retrospective case series was conducted in a community setting, where 9 patients (average age 57.4 years, ranging from 37 to 77 years) were identified as having experienced significant eye health issues while taking either semaglutide or tirzepatide
Several commenters also requested that this correction be applied retroactively to January 1, 2025, and that CMS direct MACs to reprocess affected claims
doi: 10.1191/0960327104ht432oa
In the U.S., Medicare price setting begins January 1, 2028, and the compound patent expires Dec 2028, making KEYTRUDAs loss of exclusivity arguably the largest single LOE by revenue on the near-term horizon
How to Use: Squeeze a small amount onto fingertips
Investigators will share authorship